Cargando…

Smoldering mantle cell lymphoma

BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive disease, with poor prognosis and a limited survival. However, some patients with indolent MCL can survive beyond 7~10 years. These patients remain largely asymptomatic and can be in observation for a long time without any treatment. The process...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Haige, Desai, Aakash, Zeng, Dongfeng, Nomie, Krystle, Romaguera, Jorge, Ahmed, Makhdum, Wang, Michael L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732450/ https://www.ncbi.nlm.nih.gov/pubmed/29246179 http://dx.doi.org/10.1186/s13046-017-0652-8

Ejemplares similares

Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy
por: Ye, Haige, et al.
Publicado: (2018)

Spontaneous regression of mantle cell lymphoma: a report of four cases
por: Ye, Haige, et al.
Publicado: (2018)

Progress in molecular feature of smoldering mantle cell lymphoma
por: Jiang, Panruo, et al.
Publicado: (2021)

The B cell receptor signaling pathway in mantle cell lymphoma
por: Merolle, Maria I., et al.
Publicado: (2018)

Gene mutations and actionable genetic lesions in mantle cell lymphoma
por: Ahmed, Makhdum, et al.
Publicado: (2016)

NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
por: Balaji, Swathi, et al.
Publicado: (2018)

The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma
por: Huang, Shengjian, et al.
Publicado: (2018)

Current trials for frontline therapy of mantle cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2018)

NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells
por: Li, Yangguang, et al.
Publicado: (2017)

Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma
por: Jain, Preetesh, et al.
Publicado: (2023)

Dual targeting of PI3K and BCL‐2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2022)

Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment
por: Zhang, Han, et al.
Publicado: (2016)

Smoldering Multiple Myeloma
por: Gao, Minjie, et al.
Publicado: (2015)

Current overview and treatment of mantle cell lymphoma
por: Schieber, Michael, et al.
Publicado: (2018)

Emerging therapies in mantle cell lymphoma
por: Hanel, Walter, et al.
Publicado: (2020)

Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis
por: Hess, Georg, et al.
Publicado: (2015)

Microsatellite instability in the smoldering form of adult T-cell leukemia/lymphoma (ATL) in Brazil
por: Magalhães, Marcelo, et al.
Publicado: (2011)

Immunotherapeutic potential of varicella vaccine in smoldering and cutaneous adult T-cell leukemia/lymphoma
por: Amano, M, et al.
Publicado: (2014)

Management of mantle cell lymphoma in the elderly patient
por: Doorduijn, Jeanette K, et al.
Publicado: (2013)

Management of Drug Resistance in Mantle Cell Lymphoma
por: Roué, Gaël, et al.
Publicado: (2020)

Advances in the assessment of minimal residual disease in mantle cell lymphoma
por: Jung, Dayoung, et al.
Publicado: (2020)

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma
por: Zhang, Shaojun, et al.
Publicado: (2021)

The role of B cell antigen receptors in mantle cell lymphoma
por: Fichtner, Michael, et al.
Publicado: (2017)

Nuclear Translocation of B-Cell-Specific Transcription Factor, BACH2, Modulates ROS Mediated Cytotoxic Responses in Mantle Cell Lymphoma
por: Chen, Zheng, et al.
Publicado: (2013)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

Recent Advances in the Management of Smoldering Multiple Myeloma
por: Madhira, Bhaskara Reddy, et al.
Publicado: (2020)

What Is New in the Treatment of Smoldering Multiple Myeloma?
por: Bolli, Niccolo’, et al.
Publicado: (2021)

Risk Stratification and Treatment in Smoldering Multiple Myeloma
por: Lussier, Tyler, et al.
Publicado: (2021)

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma
por: Wang, Jeffrey, et al.
Publicado: (2019)

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
por: Samad, Nousheen, et al.
Publicado: (2010)

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
por: Galimberti, S, et al.
Publicado: (2010)

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
por: Vallumsetla, Nishanth, et al.
Publicado: (2015)

Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
por: Desai, Madhav, et al.
Publicado: (2013)

Targeting Wnt pathway in mantle cell lymphoma-initiating cells
por: Mathur, Rohit, et al.
Publicado: (2015)

Educational Case: Mantle Cell Lymphoma
por: Mai, Brenda, et al.
Publicado: (2020)

Metabolic Control of Smoldering Neuroinflammation
por: Peruzzotti-Jametti, Luca, et al.
Publicado: (2021)

Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
por: Kim, E. Bridget, et al.
Publicado: (2020)

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
por: Kirschey, Sebastian, et al.
Publicado: (2012)

Mantle cell lymphoma and its management: where are we now?
por: Ladha, Abdullah, et al.
Publicado: (2019)

Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma
por: Klener, Pavel
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qdjpf0dk1rlb4n6jide6jf46rs